LabConnect Appoints Chief Operating Officer

LabConnect Appoints Chief Operating Officer

Dr. Frank D. Morrow Joins Industry's Fastest-Growing Central Lab

SEATTLE--(BUSINESS WIRE)--LabConnect, LLC, today announced the appointment of Frank D. Morrow, Ph.D., FACN, as its chief operating officer.

Dr. Morrow is a veteran of the central lab business, having served as founding executive, president and chief scientific officer at Quintiles Laboratories Worldwide, where he was responsible for the division's growth from inception to $120M in revenue, 1,000 employees, and five wholly owned central laboratory facilities worldwide over ten years. Subsequent to Quintiles, he served as Vice President, Worldwide Operations, at Quest Diagnostics Clinical Trials.

"We're pleased to have one of the industry's most experienced executives join our team," noted Eric Hayashi, LabConnect president & chief executive officer. "Frank has the right combination of operational and scientific expertise and the passion to surprise and delight our clients."

Dr. Morrow has his clinical laboratory directorship license in more than ten states, a doctorate in clinical biochemistry from the University of Georgia, and a master's degree in human physiology from Pennsylvania State University. Dr. Morrow completed post-doctoral studies at the Harvard School of Public Health in Boston before becoming Director of the Nutrition Evaluation Laboratory of the USDA Human Nutrition Research Center on Aging at Tufts University and an adjunct assistant professor of nutrition at Tufts School of Human Nutrition. Dr. Morrow has more than one hundred publications in refereed scientific journals, including five book chapters in authoritative reference books with topics spanning clinical nutrition, clinical chemistry and pharmaceutical clinical trial management.

"LabConnect represents the next generation of central labs," said Dr. Morrow. "Biopharmaceutical sponsors' increasingly complex testing requirements-both analytically and geographically-necessitate a better operating model for central laboratory services. LabConnect has integrated several of the largest and most experienced global laboratories under a highly advanced information systems platform and has the ability to expertly coordinate multiple specialty labs. Translation: Simplified and cost-effective clinical trial management. This is a high-tech, high-touch central lab."

LabConnect also announced that for the third consecutive year it has been recognized on the Inc. 5000, Inc. magazine's annual ranking of the fastest-growing private companies in America. LabConnect ranked number 1334 on the 2009 list. It had previously ranked number 176.

About LabConnect, LLC

LabConnect, LLC (www.labconnectllc.com), established in 2002, is a leading provider of central laboratory services to the biopharmaceutical industry. LabConnect's global network of laboratories provides an extensive menu of routine and specialized laboratory assays, anatomic pathology and biostorage services. LabConnect's services include general safeties, analytical and esoteric testing capabilities such as molecular diagnostics, specialized oncology assays, biomarker analysis, pharmacokinetic analysis and method development/validation.

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.